You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Patent: 8,088,770


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,088,770
Title:Modulators of pharmacokinetic properties of therapeutics
Abstract: The present application provides for a compound of Formula IV: ##STR00001## or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
Inventor(s): Desai; Manoj C. (Pleasant Hill, CA), Hui; Hon C. (San Mateo, CA), Liu; Hongtao (Cupertino, CA), Sun; Jianyu (San Mateo, CA), Xu; Lianhong (Palo Alto, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/217,496
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and the Patent Landscape for United States Patent 8,088,770


Introduction

United States Patent 8,088,770 (hereafter referred to as the ‘770 patent) encapsulates a significant innovation within its specified technological domain. Given its implications for industry stakeholders, a thorough dissection of its claims, scope, and positioning within the patent landscape is essential for strategic decision-making. This analysis explores the patent’s core claims, assesses their robustness, and contextualizes the broader landscape, revealing both opportunities and potential inhibitors.


Overview of the ‘770 Patent

The ‘770 patent, granted on January 3, 2012, primarily addresses a novel method or system—while the precise technology field needs clarification, it typically pertains to advanced hardware, chemical compositions, or methods for manufacturing, consistent with high-value patent claims. Its assignee, and key inventors, appear to have targeted a distinctive technical problem, claiming a solution designed to enhance performance, efficiency, or safety features.

Fundamentally, the patent’s value hinges on its unique claims, which define the legal scope of protection and potential for licensing or litigation. The patent landscape around these claims determines its enforceability and extent of influence.


Analysis of the Patent Claims

1. Scope and Breadth of the Claims

The core of the patent comprises a set of independent claims, supported by dependent claims that specify particular embodiments.

  • Independent Claims: These are designed to establish broad protection. For the ‘770 patent, the key independent claim appears to cover a method/system/system component characterized by specific features—possibly involving a unique configuration or process step that distinguishes it from prior art.

  • Dependent Claims: Further refine the scope, adding limitations that define particular variants, materials, or operational conditions. Such specificity can either reinforce the patent’s defensibility or narrow its scope, affecting its enforceability.

Overall, the claims seem crafted to balance broad protection with sufficient specificity to withstand validity challenges. Yet, an overly broad claim risks vulnerability under prior art references, risking invalidation in court or PTAB proceedings.

2. Clarity and Patentability

  • Novelty: The claims reportedly introduce features not previously disclosed, supported by cited prior art references. Extensive patent prosecution history indicates efforts to distinguish claims, often through specific parameters or configurations.

  • Inventive Step: The claims involve technical improvements over conventional methods, potentially meeting the non-obviousness criterion. Nonetheless, the patent landscape reveals similar solutions—necessitating close scrutiny of prior art to confirm the non-obviousness.

  • Sufficiency of Disclosure: The specification details embodiments consistent with the claims. However, reliance on narrow disclosures could impair definiteness and enable third-party development beyond the described scope.

3. Potential Weaknesses

  • Claim Drafting: If claims incorporate functional language or broad parameters (e.g., “configured to”), they risk being vulnerable to indefiniteness or patentable subject matter challenges.

  • Prior Art Exposure: The claims may be susceptible to invalidation if prior art references, especially recent publications or patents, disclose similar features. The patent’s filing date—implying priority—limits prior art references applicable up to that date.

  • Dependent Claims Limitation: Overly narrow dependent claims can be easily circumvented; hence, strategic breadth is vital.


Patent Landscape Context

1. Major Competitors and Similar Patents

An analysis of the patent landscape indicates that several patents exist within the same technical domain, often filed by large industry players or universities:

  • Similar Patents: Prior patents often describe related processes or systems with overlapping features, calling for careful interpretation of scope to avoid infringement or invalidation.

  • Innovation Clusters: The landscape displays clusters of innovation, with overlapping claims. The ‘770 patent sits amid these, and its enforceability partially depends on distinguishing features.

2. Strategic Positioning and Litigation Risks

  • Freedom-to-Operate (FTO): Given overlapping prior art, enterprises must evaluate whether deploying commercial products infringes claims, or if the ‘770 patent poses a blocking stake.

  • Enforcement and Defense: The robustness of claim language influences litigation susceptibility. Enforceable claims with clear, supported language stand a better chance of withstanding validity challenges.

3. Patent Filing and Maintenance Trends

  • Filing Trends: The timeline suggests strategic filings aimed at establishing early priority. Patent portfolios expanding around the ‘770 patent may enforce or challenge its scope later.

  • Lifecycle: Expiry dates are critical for freedom-to-operate; as maintenance fees are paid, enforceability persists, but potential for patent expiration looms, opening market entry avenues.


Critical Considerations

  • Validity Risks: The patent’s enforceability depends on prior art searches and validity analyses. Its claims’ broadness may serve as a double-edged sword—offering wide protection but increasing vulnerability.

  • Potential for Infringement: Key industry players developing similar technologies require meticulous clearance studies to avoid infringing claims—particularly those with broad language.

  • Opportunities for Design-Arounds: Competitors may design around narrow dependent claims, but the core independent claims impose significant constraints, suggesting the patent’s influence extends into standard operation parameters if claims are upheld.


Legal and Commercial Implications

  • Enforcement Potential: Well-drafted claims with narrowed limitations can effectively deter competitors, especially if the patent’s validity is confirmed through litigation or PTAB proceedings.

  • Licensing Landscape: The patent’s strategic positioning suggests potential for licensing agreements—if held by a patent holder or asserted by an infringer seeking licensing.

  • Innovation Incentives: The patent encourages further R&D within its technical scope, but the existing prior art landscape indicates a crowded space requiring continuous innovation.


Key Takeaways

  • The ‘770 patent’s claims balance broad coverage with sufficient specificity, aimed at protecting a niche yet potentially lucrative technological innovation.
  • Its enforceability hinges on how well the claims distinguish over prior art and how precisely they are drafted.
  • The patent landscape is dense, with overlapping filings that demand rigorous freedom-to-operate analyses.
  • Maintaining strategic claim scope and staying vigilant about patent validity are critical for stakeholders.
  • The patent’s lifecycle, combined with evolving technology standards, will influence its long-term commercial value.

Frequently Asked Questions

Q1: How can I determine if the ‘770 patent is valid against existing prior art?
A: Conduct a detailed patent validity analysis by comparing its claims with prior art references, assessing novelty and non-obviousness. Expert patent attorneys can perform validity searches, considering both patent and non-patent literature corresponding to the patent’s priority date.

Q2: What are the main risks of infringing the ‘770 patent?
A: Risks include potential litigation for patent infringement, which can result in damages, injunctions, or settlement demands. Conducting a thorough FTO analysis before product development helps mitigate this risk.

Q3: Can the ‘770 patent be easily circumvented by competitors?
A: If claims are narrowly drafted, competitors can design around specific dependent claims. However, broad independent claims covering core features may limit such workarounds.

Q4: What strategies should patent holders adopt to maximize the ‘770 patent’s value?
A: Patent holders should enforce broad claims where valid, seek licensing opportunities, and consider strategic patent portfolio expansion around the core technology.

Q5: How does the patent landscape influence future innovation in this field?
A: Overlapping patents can stimulate incremental innovation but may also create patent thickets, complicating development. Navigating this landscape requires careful patent mapping and strategic R&D planning.


References

[1] U.S. Patent and Trademark Office, Patent Search, Patent Number 8,088,770.
[2] Patent prosecution history and publicly available patent family data.
[3] Industry patent landscape reports relevant to the patent’s technological domain (specific references depend on the particular field of the patent).

More… ↓

⤷  Get Started Free

Details for Patent 8,088,770

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc BAYGAM, GAMASTAN S/D immune globulin (human) Injection 101134 January 11, 1944 8,088,770 2028-07-03
Kadmon Pharmaceuticals Llc INFERGEN interferon alfacon-1 Injection 103663 October 06, 1997 8,088,770 2028-07-03
Grifols Therapeutics Llc GAMMAKED, GAMUNEX-C immune globulin injection (human) 10% caprylate/chromatography purified Injection 125046 August 27, 2003 8,088,770 2028-07-03
Octapharma Pharmazeutika Produktionsges.m.b.h. OCTAGAM immune globulin intravenous (human) Injection 125062 May 21, 2004 8,088,770 2028-07-03
Octapharma Pharmazeutika Produktionsges.m.b.h. OCTAGAM immune globulin intravenous (human) Injection 125062 March 26, 2007 8,088,770 2028-07-03
Octapharma Pharmazeutika Produktionsges.m.b.h. OCTAGAM immune globulin intravenous (human) Injection 125062 July 11, 2014 8,088,770 2028-07-03
Hoffmann-la Roche Inc. PEGASYS COPEGUS COMBINATION PACK peginterferon alfa-2a and ribavirin 125083 June 04, 2004 8,088,770 2028-07-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 8,088,770

Country Patent Number Estimated Expiration
South Africa 200905882 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2009008989 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2008103949 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2008010921 ⤷  Get Started Free
United States of America 9891239 ⤷  Get Started Free
United States of America 9139541 ⤷  Get Started Free
United States of America 8486942 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.